Linical Co., Ltd.

Equities

2183

JP3974530002

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 07:00:00 13/05/2024 BST			5-day change	1st Jan Change
408 ^JPY	-1.45%		-1.69%	-23.02%

04-12	Linical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	CI
02-21	Linical Cuts Revenue, Earnings Forecast on Lower-Than-Expected Sales, Extraordinary Losses	MT

Linical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022

February 14, 2022 at 07:10 am

Linical Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2022. For the period, the company expects net sales to be JPY 10,700 million and operating income to be JPY 683 million.

Latest news about Linical Co., Ltd.

Linical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	04-12	CI
Linical Cuts Revenue, Earnings Forecast on Lower-Than-Expected Sales, Extraordinary Losses	02-21	MT
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024	02-14	CI
Linical Seeks Listing on Standard Market Following Revised Tokyo Stock Exchange Rules	27/09/23	MT
Linical Co., Ltd. Provides Dividend Forecast for the Year Ending March 31, 2024	14/08/23	CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024	14/08/23	CI
Linical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	15/05/23	CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024	15/05/23	CI
Linical Co., Ltd. Provides Year Ending Dividend Forecast for the Year Ending March 31, 2024	15/05/23	CI
Linical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023	15/05/23	CI
Linical Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2023	14/02/23	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	14/02/23	CI
Linical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023	27/12/22	CI
Linical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2023	27/12/22	CI
Science 37 Holdings, Linical Americas to Deploy Decentralized Clinical Trial Services	17/11/22	MT
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	14/11/22	CI
Linical Co., Ltd.(TSE:2183) dropped from S&P Global BMI Index	19/09/22	CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	12/08/22	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	12/08/22	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	16/05/22	CI
Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 9, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	16/05/22	CI
Linical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022	14/02/22	CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	14/02/22	CI
Linical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2022	12/11/21	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2022	12/11/21	CI

Chart Linical Co., Ltd.

Duration

Period

More charts

Company Profile

Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

Sector

Biotechnology & Medical Research

Calendar

14/05/2024 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Linical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

414 JPY

Average target price

500 JPY

Spread / Average Target

+20.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LINICAL CO., LTD.	-23.02%	59.99M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research